Immunocore Holdings (IMCR) reported its second quarter and six month results on August 6, 2026, with higher revenue and a move from a net loss to net income over the half year period.

At a share price of US$34.21, Immunocore Holdings shows a 90 day share price return of 18.25%, while the 1 year total shareholder return of 5.88% contrasts with a 3 year total shareholder return that is down 42.85%. This suggests that momentum has been rebuilding more recently following the stronger first half results.

If Immunocore Holdings has your attention after these earnings, it can be helpful to see how other healthcare companies exposed to artificial intelligence are trading right now through 41 healthcare AI stocks

Immunocore Holdings has moved back into profit, while the share price still sits well below many intrinsic value estimates. The gap between that US$34.21 price and fair value assumptions is what really matters next.

Most Popular Narrative: 48.6% Undervalued

Immunocore Holdings is trading at US$34.21 against a most-followed narrative fair value of US$66.57, which frames the current share price as a steep discount.

Significant cash balance ($883 million) and disciplined SG&A spend provide Immunocore with the resources and strategic flexibility to advance its clinical portfolio and capitalize on long-term industry trends, supporting revenue growth and potential positive net margins in the future.

To see how this cash position, projected revenue build and anticipated margin profile are incorporated into that higher fair value, review the full narrative for the detailed connections.

Result: Fair Value of $66.57 (UNDERVALUED)

However, Immunocore Holdings still faces key risks, including heavy reliance on KIMMTRAK and rising R&D spending that could pressure margins if trial outcomes or reimbursement terms disappoint.

Another View on Immunocore Holdings Valuation

The most followed narrative suggests Immunocore Holdings is heavily undervalued at US$34.21 compared with a fair value of US$66.57. Yet its P/S ratio of 4.1x sits well below the US Biotechs industry at 10.9x and the peer average of 16.6x, while sitting above a fair ratio of 3.5x.

That mix of a low current P/S against industry and peers, but a premium to the fair ratio, hints at both potential opportunity and valuation risk if sentiment or revenue expectations change. The key question is which reference point investors will lean on next: the market or the fair ratio.

Next Steps

Given the mixed messages from Immunocore Holdings' valuation and narrative signals, it makes sense to move quickly and test the numbers yourself. To see what is driving the optimism and which rewards stand out most clearly, review the 3 key rewards

Looking for more investment ideas beyond Immunocore Holdings?

You have seen how Immunocore Holdings stacks up. Now broaden your watchlist with fresh ideas that could sharpen your overall portfolio positioning.

• Target income resilience by reviewing companies identified as potential 10 dividend fortresses that may help support more reliable cash flows from dividends.
• Hunt for mispriced quality by using the screener of screener containing 19 high quality undiscovered gems that many investors may not be watching closely yet.
• Strengthen downside protection by focusing on the 80 resilient stocks with low risk scores and see which stocks score well on risk factors that matter to you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.